No, Stevens-Johnson Syndrome is NOT a Common Adverse Effect of Terbinafine
Stevens-Johnson syndrome (SJS) is a rare but serious adverse reaction to terbinafine, occurring in approximately 0.04% of patients treated with oral terbinafine. 1
Understanding the Risk Profile
The British Association of Dermatologists' 2014 guidelines explicitly state that while oral terbinafine is "generally well tolerated," there have been "rare reports of serious adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis" 1. A postmarketing surveillance study documented that the incidence of serious adverse events overall was only 0.04% 1.
The FDA drug label for terbinafine confirms this risk profile, listing SJS and toxic epidermal necrolysis in the warnings and precautions section, but clearly indicating these are rare occurrences 2.
What IS Common with Terbinafine?
The most common adverse effects (occurring in >2% of patients) are 2:
- Gastrointestinal symptoms (49%): nausea, diarrhea, dyspepsia, abdominal pain, flatulence
- Dermatological events (23%): rash, pruritus, urticaria, eczema
- Headache
- Taste disturbance (though this can rarely be permanent and patients must be warned)
- Liver enzyme abnormalities
Critical Clinical Implications
When to Stop Terbinafine Immediately
Discontinue terbinafine tablets immediately if signs or symptoms of drug reaction occur 2. This includes:
- Development of widespread rash with blistering
- Mucosal involvement (oral, ocular, genital)
- Fever with skin eruption
- Any signs suggesting SJS/TEN
Important Caveats
Terbinafine can induce or aggravate subacute cutaneous lupus erythematosus, and there are case reports of SJS occurring concomitantly with lupus exacerbation 3, 4. The drug should be prescribed with caution in patients with:
- Pre-existing systemic lupus erythematosus or subacute cutaneous lupus
- Psoriasis (can trigger or worsen psoriatic lesions)
- Photosensitivity
- Positive antinuclear antibodies
- History of autoimmune conditions
In patients with lupus or psoriasis, azole antifungals (itraconazole or fluconazole) may be safer alternatives 4.
Monitoring Requirements
While SJS is rare, baseline monitoring is recommended 1:
- Liver function tests and complete blood count before starting therapy
- Particularly important in patients with history of hepatotoxicity, heavy alcohol use, or hematological abnormalities
- Re-evaluation at 3-6 months after treatment initiation
The Bottom Line
SJS from terbinafine is a rare but potentially life-threatening complication that requires immediate drug discontinuation. However, it should not be considered a "common" adverse effect—the vast majority of patients tolerate terbinafine well, with only minor gastrointestinal or dermatological symptoms. The key is appropriate patient selection, baseline screening, and vigilant monitoring for early warning signs of severe cutaneous reactions.